The U.S. Food and Drug Administration approved Infuse for only anterior approach lumbar fusion surgery.  Many patients have received Infuse in off-label uses in either the lumbar or cervical spine.  The FDA has not authorized Infuse in either lateral or posterior approach lumbar fusion surgeries or for use in the cervical spine.

 The patient must be informed of off-label or experimental use of a drug or medical devise by a physician prior to surgery and full disclosure of the risk.  Many patients who received off-label use of Infuse in their spine were not informed.  Specific side effects reported from the off-label use of Infuse:

• Ectopic bone growth or uncontrolled bone growth in the spinal canal
• Ongoing or chronic radiating pain in the legs or arms called radiculopathy or radiculitis
• Sterility, retrograde ejaculation, or other urogenital injuries in male patients
• In cervical spine surgeries: acute neck swelling several days after surgery resulting in death or permanent injury
• Nerve injuries causing chronic pain

If you are a family member were seriously injured after receiving Infuse, Please fill out the Contact Us section below for a confidential case evaluation.

The Type-2 diabetes drug Actos (also marketed as Duetact, Actoplus and Actoplus Met), which was manufactured, developed and distributed by Takeda Pharmaceuticals, has recently been linked to an increased risk of bladder cancer.

In June of 2011, Actos was removed from the markets in France and Germany after studies revealed a potential increased risk of bladder cancer associated with Actos.  Shortly thereafter, also in June of 2011, the U.S. Food and Drug Administration (FDA) issued a warning that Actos may be linked to an increased risk of bladder cancer, especially in those who have taken Actos for more than a year.  Consequently, the FDA required the maker of Actos to include information about the risk of bladder cancer associated with Actos on its warning label.

The attorneys at Pendley, Baudin & Coffin are here to help you with your Actos lawsuit.  Our firm has more than 20 years in pharmaceutical litigation and has represented thousands of consumers who have been injured by pharmaceutical drugs such as Actos.  We have helped others triumph over major pharmaceutical companies, and we can help you find justice as well. 

If you or a loved one is a diabetic who has been diagnosed with bladder cancer while taking Actos, you have the legal right to seek compensation for your losses and suffering through an Actos lawsuit.  For a free consultation to speak with a qualified and experienced lawyer, who will listen to your story, answer your Actos related questions, discuss your options, and offer the help you need to obtain the compensation you deserve, we invite you to phone us at the numbers listed on our website or to fill out the contact us listed below. 

On Thursday, U.S. District Judge Eldon Fallon in New Orleans announced the settlement.  The settlement calls for Knauf to create an uncapped fund to pay for repairs for an estimated 4,500 homes in Florida, Louisiana, Mississippi and Alabama.  Judge Fallon must sign-off on the settlement before any money is distributed.  The estimated value of the settlement is between $800 million and $1 billion.

Mr. Ansardi claims that United States Maritime Services, Inc., contracted with boat owners to help BP clean up the Gulf Coast following the BP oil spill, but it failed to fully pay him. Mr. Ansardi’s agreement with United States Maritime Services, Inc., like all of its agreements with boat owners, committed him to make his boat available twenty-four hours a day until the end of the contract. He could not use his boat for any other purpose during the term of the contract.

United States Maritime Services, Inc., however, only paid Mr. Ansardi for use of the boat for days during the contract period when the boat was actually used. Mr. Ansardi claims that United States Maritime Services, Inc. owes him payment for all days the boat was under contract, even those days when the boat was not put to physical use.

According to Dan A. Robin, an attorney for Mr. Ansardi, more than 500 boat owners contracted with United States Maritime Services, Inc. to put their boats into the VOO program and they all have been short- changed on their contracts. “It’s time for these boat owners to be paid the money they are owed,” he said.

The suit is captioned Lester Ansardi, et al. v. United States Maritime Services, Inc., et al., Civil District Court, Parish of Orleans, State of Louisiana, Civil Action No. 2011-11436. A copy of the complaint is available at www.pbclawfirm.com.

Mr. Ansardi is represented by Christopher L. Coffin, Dan A. Robin, Jr., Kevin I. Goldberg and Gary E. Mason. Christopher L. Coffin of Pendley, Baudin & Coffin, L.L.P., LLP (New Orleans & Plaquemine, Louisiana) has years of experience litigating complex cases involving environmental contamination, product liability, toxic torts and consumer fraud in many national lawsuits representing thousands of individuals. Dan A. Robin, Jr. (Chalmette, Louisiana) has over 15 years of litigation and trial experience on behalf of injured persons. Gary

E. Mason of Mason LLP (Washington, D.C.) frequently represents victims of environmental incidents, including thousands of Alaskans in the Exxon Valdez litigation. Kevin I. Goldberg of Goldberg, Finnegan & Mester, LLC (Silver Spring. Maryland) has been named in Maryland Superlawyers Magazine and D.C. Superlawyers Magazine from 2007 through 2010 and has been vigorously representing Gulf oil spill victims since the spill.

The FDA approved the device on a humanitarian exemption basis; this allows for devices that could potentially benefit fewer than 4,000 patients a year.  They required no evidence that it was effective, only that the risk was outweighed by benefits. This study questions whether approving such a medical device ended up putting patients at risk.

If you or a family member received one of these stents please click here to contact one of the attorneys at Pendley, Baudin and Coffin and have your potential case confidentially evaluated.

DuPont introduced the Imprelis herbicide in October 2010.  Imprelis is used for killing broadleaf weeds like dandelion and clover and is sold to lawn care professionals only.  DuPont claimed the herbicide was safer for the environment than 2,4-D Dichlorophenoxyacetic acid and other older herbicides; they marketed Imprelis as a low environmental impact herbicide.  Landscapers who used Imprelis began reporting dead and damaged trees.  Wilting and browning leaves at the end of branches is the most obvious symptom of Imprelis tree damage and curling and twisting of new growth has also been observed.

PBC’s lawsuit is brought on behalf of individuals and entities whose property was exposed to Imprelis directly or indirectly, in particular those who own property on which Imprelis was applied and trees and other vegetation whose roots extend under property on which Imprelis was applied or property onto which Imprelis migrated.

If DuPont Imprelis herbicide was used on or near your property and trees have been damaged or died since the application, contact the attorneys at Pendley, Baudin and Coffin, L.L.P. to have your potential case confidentially evaluated.

A warranty is offered with these products, but those that have experienced problems with CertainTeed fiber cement complain that the manufacturer did not abide by the terms of its contracts.

If you have experienced problems with CertainTeed fiber cement siding and would like to have your case evaluated by the attorneys of Pendley, Baudin & Coffin, L.L.P. fill out the case evaluation form below and we will contact you to determine if you are eligible to participate in a lawsuit to recover compensation for damages.